As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1
Methylcobalamin is the active forms of B12, leading to greater overall benefits
The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption
Proper storage and handling ensures reproducible results across multiple experiments and research teams
Does glutathione actually help hangovers or is it just marketing
Responses of gut microbiota to diet composition and weight loss in lean and obese mice (in Eng)